The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020crobial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

Board Of Directors

 

 
Torsten Goesch
MD, MBA, PhD,

Chairman of the Board
since 2015
dependent
Lena Degling
Wikingsson, MD,
Board member
since 2021
independent
Achim Kaufhold
MD,
Board Member
since 2021
independent

Marianne Kock
MSc, MBA,
Board member
since 2021
independent

Professional experience Professional experience Professional experience Professional experience
  • Dr. Torsten Goesch has been Director of Rosetta Capital’s secondary life science investments since 2002

  • Has served as the General Manager for the German Speaking Countries at Biogen from 1997-1999

  • Commercial Head of Merck KGaA’s worldwide generics drug business Merck Generics
  • Currently serves as CEO of Dilafor

  • Board member of the Swedish companies, Simplexia, XNK Therapeutics and Alzinova.

  • Former CEO of Independent Pharmaceutica and Avaris

  • Non-executive Director of Next Cell Pharma, Avaris and Eurocine Vaccines
  • Has previously served as CEO of Affitech and Pharmexa (both companies merged)

  • CMO of companies such as Basilea Pharmaceutica, Chiron (acquired by Novartis) and Berna Biotech (now Johnson & Johnson)
  • Currently serves as General Manager at Ferring Pharmaceuticals’ IPC Development Unit in Copenhagen.

  • Board member of Ferring Pharmaceutical (DK), Syntese (DK), Izvarino Pharma (Rus), NanoPharm (Rus) and Asarina (SE)

  • Previously, board member of Fertin Pharma (DK), Bionor Pharma (NO), Egalet (DK), Forward Pharma (DK) and Gastrotech Pharma (DK)
Educational background Educational background Educational background Educational background
  • Doctor of Medicine (MD) and Ph.D. from Heinrich Heine University Düsseldorf

  • Master of Management (MBA) from Northwestern University’s
    J.L. Kellogg Graduate School of Management
  • Lena Degling Wikingsson holds a Ph.D. in Pharmaceutical Science and a Master of Science (MSc) in Pharmacy, both from Uppsula University, Sweden
  • Doctor of Medicine from the University of Cologne and holds a professorship in Medical Microbiology and Infectious Diseases at the University of Aachen, Germany
  • Master’s degree in Pharmacy from Danish University of Pharmacy

  • Executive Master’s degree in Business Administration from Scandinavian International Management Institute

 

 

 

 

 

 

 

 

 

 

Henrik Moltke
MSc,
Board Member
since 2021
independent

Hanne Mette Dyrlie Kristensen, MSc, MBA,
Board member
since 2021
independent

Mattias Klintemar
MBA,
Board Member
since 2021
dependent

Professional experience Professional experience Professional experience
  • Currently serves as CFO of FluoGuide A/S (Nasdaq First North Growth Market Stockholm)

  • Board member at Hartmanns A/S

  • Board member at Initiator Pharma

  • Former CFO at Oncology Venture A/S (Nasdaq First North Growth Market Stockholm)

  • Currently serves as CEO, The Life Science Cluster

  • Founder, Oslo Life Science Advisors AS

  • Has served as Special advisor, responsible for Life Sciences / Health, Invest In Norway & Innovation Norway

  • Member of the Board of Regionale Forskningsfond, RFF Viken

  • CEO of Targovax AS
  • Currently serves as Director of Investments at Östersjöstiftelsen

  • Has served as CEO at Morphic Technologies AB,

  • CFO at Hexaformer

  • Chairman of the board at Dilafor

  • Board member at Oatly, Phoniro, Pharmanest AB, Cell impact and Axelar
Educational background Educational background Educational background
  • Msc (Econ) – cand.merc., Strategy and International Economics at Copenhagen Business School
  • Master of Technology Management (MTM) from Norwegian University of Science and Technology and MIT, Sloan School of Management, Boston

  • Cand. Scient. in Chemistry, specialization in Biochemistry at University of Oslo
  • Bachelor of Business Administration (B.B.A.), Accounting and Finance from Karlstad Universit